HLB Appoints Jinyang Gon and Baek Yoon-gi as Co-CEOs... Kim Dong-geon Specially Dispatched to the US

HLB has made personnel changes by specially dispatching President Kim Dong-geon as head of the U.S. subsidiary and appointing Baek Yoon-gi as the new co-CEO, based on the judgment that the approval and commercialization of the targeted anticancer drug 'Rivoceranib' are imminent.

HLB recently appointed Baek Yoon-gi as the new co-CEO (left) and specially dispatched President Kim Dong-geon as the head of the U.S. subsidiary, the company announced on the 6th.
[Photo by HLB]

According to HLB on the 6th, the existing co-CEO system led by Chairman Jin Yang-gon and President Kim Dong-geon was changed to a co-CEO system of Chairman Jin Yang-gon and President Baek Yoon-gi through a disclosure yesterday. President Kim Dong-geon has been specially dispatched as head of HLB's U.S. subsidiary to organically manage HLB's entire U.S. business on-site and strengthen the collaboration system among affiliates such as Elevate, Immunomic, and Verismo.

The newly appointed CEO Baek Yoon-gi joined the HLB Group in 2020 as Vice President of HLB Global after serving as head of finance at Daewoo Group, managing director at Daewoo Capital, and CEO of YG Partners. Since then, he has served as Vice President of HLB Life Science and Chief Operating Officer (COO) of HLB, overseeing overall business management and fund operations across the group. With the recent successive mergers and acquisitions (M&A) incorporating new affiliates and significantly strengthening diagnostic business capabilities, Baek, who has a high understanding of overall group operations, is expected to lead the post-merger integration (PMI) process and sound management.

Meanwhile, President Kim Dong-geon, who was appointed co-CEO of HLB in 2021, is heading to the U.S. as procedures for FDA approval of the combination therapy of Rivoceranib and Camrelizumab for liver cancer are underway. It is explained that to enhance the value of Rivoceranib and prepare for HLB's global leap, President Kim Dong-geon, who graduated from Harvard University and gained years of practical experience at the U.S. law firm Latham & Watkins and Wall Street's Deutsche Bank, is considered the best candidate to oversee HLB's U.S. business. HLB also added that before joining HLB, President Kim held positions such as CEO of Eugene Asset Management, CFO of E-Land Group, and Vice Chairman of Danal, demonstrating high expertise in corporate management including legal affairs, finance, accounting, and new business development.

Kim Jong-won, Chief People Officer (CPO) of HLB Group, said, “HLB is setting treatment and diagnostics as two major growth pillars and is implementing the goal of becoming a global new drug and bio company through the approval of Rivoceranib for liver cancer and strengthening diagnostic technology.” He explained, “This personnel move is a strategic step to enhance the collaboration system between the parent company and affiliates, as well as to raise HLB’s status and future profits in the key business location of the U.S.”

This content was produced with the assistance of AI translation services.